絞り込み

16616

広告

吉本興業社長「つらい思いさせ申し訳ない」処分撤回の考え (NHK)

所属するお笑い芸人が、反社会的勢力の主催する会合に参加して金銭を受け取っていた問題への対応を巡り、吉本興業の岡本昭彦社長が22日、初めて記者会見し、「反社会勢力...

  1. 吉本社長「事務所代表しておわび」 (NH...
  2. 令和元年度「『見える』安全活動コンクール...
  3. 第14回「若年者ものづくり競技大会」を福...
  4. 調達情報 令和2年度介護事業実態調査(介...

ニュース一覧

How I Treat Chronic Myeloid Leukemia in Children and Adolescents.

著者 Hijiya N , Suttorp M
Blood.2019 Mar 27 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (18view , 0users)

Full Text Sources

Evidence-based recommendations have been established for treatment of chronic myeloid leukemia (CML) in adults treated with tyrosine kinase inhibitors (TKIs), but the rarity of this leukemia in children and adolescents makes it challenging to develop similar recommendations in pediatrics. In addition to imatinib, which was approved for pediatric CML in 2003, the second-generation TKIs dasatinib and nilotinib were recently approved for use in children, thus expanding the therapeutic options and pushing allogeneic stem cell transplantation to a third-line treatment for most pediatric cases. Yet without sufficient data on efficacy and safety specific to pediatric patients, the selection of a TKI continues to rely on clinical experience in adults. Here, we present 4 case scenarios highlighting common yet challenging issues encountered in the treatment of pediatric CML (suboptimal response, poor treatment adherence, growth retardation, and presentation in advanced phases). Limited experience with very young children, the transition of teenagers to adult medicine, and the goal of achieving treatment-free remission for this rare leukemia are additional significant obstacles that require further clinical investigation through international collaboration.
PMID: 30917954 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード